| Description | BCLAF1 Human Pre-designed siRNA Set A contains three designed siRNAs for BCLAF1 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control. Components BCLAF1 siRNA-1: 5 nmol (HPLC) BCLAF1 siRNA-2: 5 nmol (HPLC) BCLAF1 siRNA-3: 5 nmol (HPLC) siRNA Negative BCLAF1 Human Pre-designed siRNA Set A contains three designed siRNAs for BCLAF1 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control. Components BCLAF1 siRNA-1: 5 nmol (HPLC) BCLAF1 siRNA-2: 5 nmol (HPLC) BCLAF1 siRNA-3: 5 nmol (HPLC) siRNA Negative Control: 5 nmol (HPLC) FAM-labeled siRNA Negative Control: 5 nmol (HPLC) GAPDH siRNA Positive Control:5 nmol (HPLC)... Read More | Inquire | Dezamizumab (anti-Serum Amyloid P) is a fully humanized recombinant monoclonal IgG1 anti-serum amyloid P component (SAP) antibody, with potential anti-amyloid activity. Dezamizumab (anti-Serum Amyloid P) triggers immunotherapeutic clearance of amyloid. Dezamizumab (anti-Serum Amyloid P) can be used Dezamizumab (anti-Serum Amyloid P) is a fully humanized recombinant monoclonal IgG1 anti-serum amyloid P component (SAP) antibody, with potential anti-amyloid activity. Dezamizumab (anti-Serum Amyloid P) triggers immunotherapeutic clearance of amyloid. Dezamizumab (anti-Serum Amyloid P) can be used in research of Amyloid light-chain (AL) amyloidosis... Read More | Ganglioside GT1b is a brain ganglioside. It is composed of a neutral tetra-saccharide core, with one or two sialic acid on the internal galactose and an extra sialic acid on the non-reducing terminal of galactose | Purity>95% (SDS-PAGE) Endotoxin level<1.0 EU/µgFunctionInhibits the synthesis of a number of cytokines, including IFN-gamma, IL-2, IL-3, TNF and GM-CSF produced by activated macrophages and by helper T-cells |